TORNTPHARM.BOTORNTPHARM.BO
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-0.64%
↓ 104% below average
Average (39q)
17.85%
Historical baseline
Range
High:319.51%
Low:-76.36%
Volatility
2217.4%
High variability
| Period | Value |
|---|---|
| Q3 2025 | -0.64% |
| Q2 2025 | 4.67% |
| Q1 2025 | -0.66% |
| Q4 2024 | 4.14% |
| Q3 2024 | 7.41% |
| Q2 2024 | -2.88% |
| Q1 2024 | 9.45% |
| Q4 2023 | -3.79% |
| Q3 2023 | 2.33% |
| Q2 2023 | -75.00% |
| Q1 2023 | 319.51% |
| Q4 2022 | 1.65% |
| Q3 2022 | -0.82% |
| Q2 2022 | -76.36% |
| Q1 2022 | 319.51% |
| Q4 2021 | -5.38% |
| Q3 2021 | 4.00% |
| Q2 2021 | -15.54% |
| Q1 2021 | 32.14% |
| Q4 2020 | -5.88% |
| Q3 2020 | 10.19% |
| Q2 2020 | -8.47% |
| Q1 2020 | 7.27% |
| Q4 2019 | -15.38% |
| Q3 2019 | -4.41% |
| Q2 2019 | -2.86% |
| Q1 2019 | 3.70% |
| Q4 2018 | -0.74% |
| Q3 2018 | 6.25% |
| Q2 2018 | -72.17% |
| Q1 2018 | 296.55% |
| Q4 2017 | 8.41% |
| Q3 2017 | 5.94% |
| Q2 2017 | -25.74% |
| Q1 2017 | 43.16% |
| Q4 2016 | -14.41% |
| Q3 2016 | 21.98% |
| Q2 2016 | -63.01% |
| Q1 2016 | 0.00% |
| Q4 2015 | 0.00% |